Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

5.79
-0.8300-12.54%
Post-market: 6.400.6100+10.54%19:50 EDT
Volume:143.10K
Turnover:849.66K
Market Cap:125.63M
PE:-1.80
High:6.47
Open:6.47
Low:5.62
Close:6.62
52wk High:17.94
52wk Low:3.35
Shares:21.70M
Float Shares:11.17M
Volume Ratio:1.22
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2080
EPS(LYR):-0.7400
ROE:-66.02%
ROA:-40.38%
PB:1.68
PE(LYR):-7.82

Loading ...

Aardvark Therapeutics, Inc. Expected to Post a Loss of 87 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Aardvark Therapeutics Price Target Announced at $6.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 20

Aardvark Therapeutics Announces Annual Shareholder Meeting

Reuters
·
Jun 30

Aardvark Therapeutics Implements Executive Retention Bonus Agreements

TIPRANKS
·
Jun 13

Aardvark Therapeutics offers CFO Nelson Sun USD 346,500 retention bonus package

Reuters
·
Jun 13

FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4

TIPRANKS
·
May 18

Aardvark Therapeutics downgraded to Underperform from Buy at BofA

TIPRANKS
·
May 16

Top Midday Decliners

MT Newswires Live
·
May 16

Sector Update: Healthcare

MT Newswires Live
·
May 16

Aardvark Therapeutics Cut to Neutral From Buy by BTIG

Dow Jones
·
May 15

Aardvark Therapeutics Inc trading resumes

TIPRANKS
·
May 15

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM

Reuters
·
May 15

Aardvark Therapeutics downgraded to Neutral from Buy at BTIG

TIPRANKS
·
May 15

Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk

Dow Jones
·
May 15

Aardvark Therapeutics Inc : Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
May 15

Morgan Stanley Downgrades Aardvark Therapeutics to Underweight From Equalweight, Cuts Price Target to $3 From $7

MT Newswires Live
·
May 15

Stocks to Watch: Figma, Aardvark, Gambling.com, P3 Health

Dow Jones
·
May 15

Aardvark Therapeutics announces FDA clinical hold on ARD-101

TIPRANKS
·
May 15

Aardvark Therapeutics Says FDA Placed Hold on ARD-101 Trials

Dow Jones
·
May 15

FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome

Reuters
·
May 15